Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an overall 5-year survival rate of 9.3%, and this malignancy is expected to become the second leading cause of cancer-related death by 2030. Gemcitabine resistance develops within weeks of PDAC patient's...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer management and research 2020-01, Vol.12, p.4645-4665
Hauptverfasser:	Chen, Ya-Hui, Chen, Yi-Chun, Lin, Chi-Chen, Hsieh, Yao-Peng, Hsu, Chien-Sheng, Hsieh, Ming-Chia
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Cell death Chemotherapy Enzymes Gemcitabine Health aspects Life Sciences & Biomedicine mia paca-2 Oncology Original Research Pancreatic cancer Pitavastatin Science & Technology Statins synergistic anticancer Zoledronic acid
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!